Introduction
Adjuvant systemic treatments, such as chemotherapy and hormonal treatment, have been used widely to treat breast cancer. 1 Hormonal treatment is recommended for women with hormone receptor-positive breast cancer, accounting for at least two-thirds of all breast cancer cases. 2, 3 The two most common hormonal treatments are tamoxifen and aromatase inhibitors (AIs).
Tamoxifen, a selective estrogen receptor modulator (SERM), was introduced in the 1970s. Tamoxifen is currently recommended to treat Aromatase inhibitors are associated with a higher fracture risk than tamoxifen: a systematic review and meta-analysis early and advanced-stage breast cancer in premenopausal and postmenopausal women. 4 Tamoxifen is also an optional treatment in women with stage 0 (in situ) breast cancer. 5 Tamoxifen reduces the available estrogen to cancer cells by competitively inhibiting the binding of estrogen to the estrogen receptors on breast tissues. The effect of tamoxifen on bone tissues is inconsistent across studies and seems to differ by menopausal status. Tamoxifen caused a bone mineral density (BMD) decrease in healthy premenopausal women but a BMD increase in healthy postmenopausal women. 6 In women diagnosed with breast cancer, tamoxifen preserves bone mass in premenopausal women, and either slightly increases or decreases BMD in postmenopausal women. [7] [8] [9] [10] [11] [12] Tamoxifen may have a beneficial effect on bone health in women diagnosed with breast cancer. However, tamoxifen has not been approved for the treatment or prevention of osteoporosis in any populations by the US Food and Drug Administration.
AIs were introduced in the early 2000s. AIs are currently recommended to treat early and advanced-stage breast cancer in postmenopausal women, especially women unable to tolerate tamoxifen or at higher risk of cancer relapse. AIs reduce the circulating estrogen levels by inhibiting the aromatase enzyme from converting androgen into estrogen in nonovarian tissues. AIs significantly increase bone loss 10, 13 and are associated with higher fracture risks in several major trials. 14, 15 However, AI-associated fracture risk has not been reviewed systematically.
The initial goal of this study was to determine the effects of adjuvant systemic breast cancer treatments on BMD changes and fracture risk, compared with locoregional treatments (i.e. surgery and radiation therapy) or no breast cancer treatment in women aged 65 and under. In women diagnosed with breast cancer, younger women (aged 65 and under) are less likely than older women to be assessed for fracture risk before fractures occur using 10-year fracture risk assessment tools or BMD testing. This is because cancer treatment-associated fracture risk is not universally recognized as an indicator in the 10-year fracture risk assessment tools and BMD testing. 16 Fractures, however, have a higher clinical impact on healthcare systems than BMD changes. Tamoxifen and AIs are used to treat breast cancer more often than other adjuvant systemic treatments. Hence, we focussed our research questions on the differential fracture risks associated with tamoxifen and AIs in younger women aged 65 years and under, and diagnosed with nonmetastatic breast cancer. This study is targeting younger women, as it is more challenging to identify high-risk young women before fractures occur.
Method
This was a systematic review with meta-analysis study using aggregate data from randomized controlled trials (RCTs) and cohort studies on fracture risks associated with tamoxifen and AIs in younger women aged 65 years and under, and diagnosed with nonmetastatic breast cancer. We registered the review protocol at PROSPERO (registration number CRD42015015604, available at: https://www.crd.york.ac.uk/PROSPERO/). We reported study results using criteria from the Preferred Reporting Items for Systematic Review and Meta-analysis Protocols (PRISMA). 17 Article search was conducted by the first author. Study selection (NR/OT for title/abstract screening; WH/ OT for full-text article review), study quality evaluation (WH/OT), and data extraction (WH/OT) were performed independently by two reviewers using Excel spreadsheets. Disagreements between reviewers were resolved by discussion. Persistent disagreements between reviewers were arbitrated by another designated team member (MD).
Search strategy
We searched PubMed, MEDLINE, CINAHL, EMBASE, and Cancerlit databases for article published from 1 January 1970 to 1 May 2015, on 3 May 2016. We included search terms "breast" and "wom*n OR female" and "tumor OR cancer OR neoplasm OR malignanc?" and "fracture OR BMD OR densit? OR densitometr? OR absorptiometry?". Studies were then limited to human studies and English language articles. Review articles were then excluded. The reference lists of the included articles were hand searched. Approximately 20% of included and excluded articles at each step of the article search were randomly reviewed to ensure proper article search strategies.
Study selection
Articles were initially screened by title and abstract, followed by full article reviews (Figure 1 ). Articles fulfilling the inclusion criteria: (a) RCTs or cohort studies; 18 (b) women diagnosed with nonmetastatic breast cancer; (c) at least one participant aged 65 years and under at baseline; (d) breast cancer treatments of tamoxifen, AIs or both; and (e) fracture outcomes, were selected. We defined the outcomes in this study as count of fracture events or participants with fractures. Articles reporting pathological fractures or any specific fracture type (e.g. spine fracture only) were excluded.
Study quality assessment
We evaluated the methodological quality of the selected articles using two separate assessment tools suggested by the Cochrane Collaboration Review Group. RCTs were evaluated using the Cochrane Risk of Bias assessment tool. Each RCT was assessed and rated as 'low risk of bias', 'high risk of bias' or 'unknown risk of bias' in the seven domains of potential bias. 19, 20 Cohort studies were evaluated in three categories using the Newcastle-Ottawa Scale with a range of zero to nine stars. Each cohort study was awarded a maximum of one star per item within the selection category with four items and outcome category with three items, and a maximum of two stars for the single item within the comparability category. 21 
Data extraction
Articles reporting data with the same follow-up times from the same independent study were collated (ID 5, 16, 18, 21, 30) . We extracted data from each included study on method, participant, treatment, fracture outcome, and factors controlled for multivariate regression models. Fracture outcome information included definition of fractures, count of fracture events (allowing more than one fracture event per participant), count of participants who developed fractures, and relative measures consisting of odds ratios (ORs), risk ratios (RRs), incidence rate ratios (IRRs), or hazard ratios (HRs) using Cox regression models.
There were two articles (ID 12, 34) each reporting combined data from two independent studies. 23, 24 Extracted data from each independent study were inadequate for meta-analysis. The authors of both articles were contacted by email but we were unable to obtain additional information on these four studies.
Data synthesis
Meta-analyses were undertaken to estimate the differential fracture risks of tamoxifen and AIs, and risks between tamoxifen and AI. Each fracture risk was stratified by three to five factors of menopausal status (prespecified), prior tamoxifen treatment, study design, AI treatment duration and AI drugs, using subgroup analysis. Menopausal status was determined using age in the two cohort studies with missing menopausal status information (ID 4, 35) .
The time effect on differential fracture risk between tamoxifen and AI was evaluated by ranges of follow-up durations (12-36, >36-60, >60-84, >84 months) and treatment period (onand post-Tam/AI treatment). Meta-analyses were conducted independently for each range of follow-up duration and treatment period. The Tam/ AI-treatment period was defined as the time period when women were receiving tamoxifen or AIs during the study period.
For each independent study with serial follow-up data, the article with the longest follow-up duration was included for each individual meta-analysis to avoid double counting of study participants. 
Results
There were 4004 articles identified, of which 2078 were duplicate articles ( Figure 1 ). This left 1926 unique articles for title/abstract screening. Of them, 1649 were excluded, leaving 277 articles for full article review. A total of 43 articles from 21 independent studies fulfilled our selection criteria and proceeded to methodological quality assessment.
Characteristics of included studies
Sixteen RCTs, four retrospective cohort studies, and one prospective cohort study were included (Table 1 ). All RCTs were designed to evaluate primary outcome of efficacy and secondary outcome of safety, including fractures, using intentto-treat analysis with the exception of one study (ID 7 
Study quality assessment
High risk of bias was observed primarily in domains of blinding of participants, blinding of outcome assessors, incomplete data, and other biases (e.g. funding) among RCTs (Appendix Figure A , online only). Unblinding of participants and their outcome assessment was observed in at least half of the RCTs that were either open RCTs or unblinded during their study periods.
Financial support from pharmaceutical companies was noted in at least 80% of the RCTs. The quality of all cohort studies was consistently high with either seven or nine out of a maximum of nine stars (Appendix Table B , online only).
Tamoxifen Three RCTs and three cohort studies compared fracture outcomes between women treated and not treated with tamoxifen (Table 2 ; Figure 2 ). One RCT with double-zero events was excluded from this meta-analysis. This analysis included 37,783 participants. Fracture risk did not differ between tamoxifen and no-tamoxifen groups (pooled RR 0.95; 95% CI 0.84-1.07). The statistical heterogeneity was low with an I 2 measure of 0% (p = 0.72). No statistical significance was reported in subgroup analyses.
Aromatase inhibitors
Three RCTs and four cohort studies compared fracture outcomes between women treated and not treated with AIs. All seven studies were included in this meta-analysis (Table 2 ; Figure   3 ). Data from the longest follow-up durations were selected for the two included studies (ID 6, 9 
Comparison of tamoxifen and aromatase inhibitors: time effect
Twenty articles from ten independent studies were included for these meta-analyses (Appendix 
Discussion
This study systematically summarized fracture risks associated with tamoxifen and AIs in women diagnosed with breast cancer. Results showed that fracture risk did not differ between women treated and not treated with tamoxifen. AI-associated fracture risk was 17 and 35% higher than the risks in the no-AI group and tamoxifen group, respectively. Compared with the tamoxifen group, increased AI-associated fracture risk trended down when the range of follow-up duration increased. AI-associated fracture risk increased by 30% during the Tam/AI treatment period but did not increase during the post-Tam/AI treatment period when compared with the tamoxifen group.
Our results showed that fracture risk did not differ between the tamoxifen and no-tamoxifen groups. This finding is consistent with the fact that tamoxifen has no effect on reducing vertebral or hip fractures in general populations. 66, 67 By contrast, tamoxifen treatment for 1 year increased the risk of trochanteric fractures (HR 2.12; 95% CI 1.12-4.01) among 1716 postmenopausal women with nonmetastatic breast cancer during the 12-year follow up in the Danish Breast Cancer Cooperative Group (DBCG) trial. 68 While evidence shows that tamoxifen may preserve BMD, tamoxifen has not been approved for the treatment or prevention of osteoporosis in any population by the US Food and Drug Administration. Women who receive tamoxifen breast cancer treatment should not skip BMD testing recommended for women diagnosed with breast cancer.
Our analysis showed that AI-associated fracture risk increased by 17 and 35% when compared with the no-AI and tamoxifen groups respectively. 9 The causes of differences in fracture risks between the treatment and post-treatment periods remain unclear. It may be due to the independent effect of AI on fracture risk, the independent effect of tamoxifen on fracture risk, or both effects combined. 76 It remains challenging to identify women at high fracture risk for treatment initiation before fractures occur. BMD measurements using dual-energy X-ray absorptiometry fail to identify everyone who will develop fractures 77, 78 while promoting lifestyle modification 79 and willingness to initiate treatment. 80 Fracture risk assessment using FRAX in this population is limited by uncertain accuracy and potential underestimation. This is because FRAX was validated using population-based studies without considering the negative effects of breast cancer treatments on bones. 81 More recently, the role of bisphosphonates (such as zoledronic acid or clodronate) has shifted from being a fracture prevention treatment to an adjuvant treatment for postmenopausal women who are diagnosed with nonmetastatic breast cancer and candidates for adjuvant systemic treatments 82 due to their abilities to reduce bone recurrence and improve survival.
Similar estimates between RCTs and cohort subgroups were observed for fracture risk in our study and for treatment effects of other noncancer drugs in other studies. 83, 84 This is likely because both RCTs and cohort studies included in this study had large participant populations, sufficient follow-up time, and low risk of bias. 85 Most included cohort studies reported relative measures adjusted for confounders, which further reduced selection bias. While at least 50% of included RCTs were unblinded to outcome assessment, it has a minimal effect on assessing objective outcomes including fractures.
Risk differences, differences in proportions of participants with fractures, between two treatments were not analyzed in this study due to significant variation in fracture rates (10 times), heterogeneous participant groups and baseline risk between studies. Number needed to treat, the average number of participants who need to be treated to prevent one fracture, was not estimated for the same reason.
All selected RCTs and cohort studies in this study reported relative measures as ORs, HRs or IRRs.
RRs were selected to estimate effect sizes, as RRs are more appropriate measures and easier to interpret than ORs. 86, 87 RRs were favored over HRs and IRRs, as RRs can be recalculated for almost all included articles except one. A generic inverse variance method with random effects model was selected in this study to account for different risk measures and heterogeneity across the included studies. Although we chose random effects models in this study, statistical heterogeneity was low (<15%) in the majority of our analyses except the analysis for post-Tam/AI treatment period and some subgroup analyses. Effect sizes were almost identical using either random or fixed effects models based on our internal analysis.
Mild to moderate statistical heterogeneity (27-67%) was noted in our meta-analyses. This statistical heterogeneity decreased significantly to 0-7% after excluding the Xu et al. study 65 (ID 37) or the Koopal et al. study 39 (ID 11) . This statistical heterogeneity associated with both these studies could be explained primarily by uncontrolled confounders due to a lack of reported adjusted relative measures. These two studies also differed from most of the included studies in this review in study setting (one center versus national/multinational) and sample size.
Limitation
This review was limited by the relative low numbers of available articles on certain subgroups, especially premenopausal groups. When comparing AIs with tamoxifen, fracture risks did not differ among subgroups of premenopausal, a mixture of pre-and postmenopausal, and postmenopausal women. Only two included studies (ID 13, 34) involved 100% premenopausal women. However, the Tamoxifen and Exemestane Trial (TEXT)/ Suppression Ovarian Functions (SOFT) study (ID 34) was not included in our reported meta-analysis, as it reported combined data from two independent studies, TEXT and SOFT. An internal analysis including data from the TEXT/SOFT study was conducted. It resulted in a similar RR estimate, with a slightly narrower 95% CI of 1.24-1.48.
Conclusion
Fracture risk is significantly higher in women treated with AIs, especially during the treatment period. Tamoxifen is not associated with lower fracture risk while tamoxifen could potentially preserve bone mass. Women who receive tamoxifen or AI breast cancer treatment should be encouraged to have BMD testing as recommended for women diagnosed with breast cancer. Optimal osteoporosis management programs, especially during the treatment period, are needed for this group of women.
